The stock price

[anonymous]

Hey it’s always darkest before the dawn, we’ve got to keep looking forward and hope that the board does the right thing.

The BoD is as much of the problem as AB and his leadership team. If they had any sense they would have already gotten rid of them for thinking the Covid taxpayer funded windfall would continue year after year. If they knew anything about the business they are in they wouldn’t let a guy with ZERO oncology experience run the part of the company that it’s bet it’s future on. The only positive thing you can say about this board is that it’s not quite as bad as Boeing’s.

 

[anonymous]

Different industry, but look at what Elon Musk did today. Yes he’s half nutty. He also takes bold action to make sure his point is made.
Tesla isn’t meeting the goal. He set a target to reduce costs. He wasn’t satisfied that his leadership was taking it seriously enough fast enough. So he eliminated almost an entire group.

contrast to Pfizer. We have missed target for multiple quarters and stock is at a decade low. The ceo and cfo talk about 6-18 month plans and have no decisive actions. They have slogans and a 175 rear view mirror. The turnaround has to happen at the top. Otherwise we are just tossing words and sliding to irrelevance

 

[anonymous]

then you have executives posting on LinkedIn about speeches they gave to groups, taking about Pfizer culture...what a joke in the middle of large layoffs and turmoil

 

[anonymous]

Pfizer had great R&D a few decades ago. When my dad worked here, I saw that there was alot of pride in how much the company invested in R&D. They had a lot of class-leading meds, and had a few "detail men" that related well to docs in their offices and in hospitals, and office staff. Back then, one rep covered large territories and were responsible for covering hospitals, nursing homes and retail pharmacies

A few years before I got here, I was told that the industry had changed, and Pfizer and Merck led that change by hiring armies of what I heard called "Ken and Barbies" to replace one rep in each of the two sales divisions. I started with PD after working in a hospital lab for 2 years after graduation, and there were several Pfizer divisions by that time. I ended up here when PD was acquired. By then, the company was nothing like the one that I had seen and heard about growing up. In my region, Pfizer's district and regional managers were just plain awful. A lot of Pfizer reps were either Ken and Barbies or ex-military officers, and the managers acted like they had discovered Lipitor and Viagra and did the research to bring them to market. Many of my PD colleagues and managers bolted for Novartis, BMS and Novartis, with a sprinkling to AZ or Glaxo

I'm guessing that the home office and R&D hired alot of Ken and Barbies, too because between piss-poor R&D results, and how our stock has tracked since Bill Steere left decades ago, we just cant seem to get it together!!

Thank you for this. It explains a lot-at least to me.

 

[anonymous]

Do you think those bozos are celebrating the stock price increase yesterday? The market got a nice surprise that PFE exceeded some quarterly guidance and we got a nice bump.

Let’s see if it holds today or retreats. i expect a retraction as investors digest the news. It’s not a good look when we continue to miss guidance on consecutive quarters, whether over or under. It shows a lack of business focus and a poor handle on the long term business operation

Please, please clear the house and bring in some leadership that can run a business

 

[anonymous]

Do you think those bozos are celebrating the stock price increase yesterday? The market got a nice surprise that PFE exceeded some quarterly guidance and we got a nice bump.

Let’s see if it holds today or retreats. i expect a retraction as investors digest the news. It’s not a good look when we continue to miss guidance on consecutive quarters, whether over or under. It shows a lack of business focus and a poor handle on the long term business operation

Please, please clear the house and bring in some leadership that can run a business

Your suggestion that effective leadership be brought in tells me that you have not worked here for an extended period, or you do not realize how far down the org chart they would have to go to change the company's trajectory. To rephrase, its not just AB and his E and C suite cronies that would have to be tossed out. In sales and in marketing, they'd have to clean house, with very few exceptions

 

[anonymous]

Different industry, but look at what Elon Musk did today. Yes he’s half nutty. He also takes bold action to make sure his point is made.
Tesla isn’t meeting the goal. He set a target to reduce costs. He wasn’t satisfied that his leadership was taking it seriously enough fast enough. So he eliminated almost an entire group.

contrast to Pfizer. We have missed target for multiple quarters and stock is at a decade low. The ceo and cfo talk about 6-18 month plans and have no decisive actions. They have slogans and a 175 rear view mirror. The turnaround has to happen at the top. Otherwise we are just tossing words and sliding to irrelevance

Yeah Musk is doing great, what an example to follow! Let’s wipe out a whole department in charge of one of Tesla’s competitive advantages? Let’s build a shitty truck instead of affordable cars people may actually want?

Taking Musk’s lead, we should just fire the sales force. Can’t see half the docs they say they do anyway

 

[anonymous]

Your suggestion that effective leadership be brought in tells me that you have not worked here for an extended period, or you do not realize how far down the org chart they would have to go to change the company's trajectory. To rephrase, it’s not just AB and his E and C suite cronies that would have to be tossed out. In sales and in marketing, they'd have to clean house, with very few exceptions

Thanks for adding context. And Yes, that is exactly the point. Bring in business leaders who will focus on the enterprise. If the right talent is not in place at each subsequent level down, they should fix it.
AB and his cronies have not done it. Find leaders who will.

 

[anonymous]

Yeah Musk is doing great, what an example to follow! Let’s wipe out a whole department in charge of one of Tesla’s competitive advantages? Let’s build a shitty truck instead of affordable cars people may actually want?

Taking Musk’s lead, we should just fire the sales force. Can’t see half the docs they say they do anyway

Yes, and thanks again for adding an example to this point. If the Sales Force or any other part of the company is not able to, have the skill to, or allowed to do their job, it’s time to make a change.

Adding context: I never said I was a Musk fanboy. Just an example that other leaders make bold choices

 

[anonymous]

To Prevnar marketers: remove the “a Pfizer Vaccine” voice over in the commercial. It’s not helpful

 

[anonymous]

Wells Fargo on latest earnings: "......points out that the quality of this beat is questionable. It seems to be largely attributed to the unexpected adjustment of Paxlovid sales, which masks the underlying performance of Pfizer’s non-COVID portfolio. Additionally, while Pfizer’s ex-COVID business observed a year-over-year growth, it mostly stemmed from newly included SGEN products. Excluding these products, the growth was modest, which raises concerns about the core business’s growth trajectory moving forward.
Furthermore, the report indicates that while Comirnaty sales were down, this did play a role in the favorable gross margin for the quarter. Prevnar sales were solid, but there are looming risks with potential competition from upcoming products such as V116. In the RSV vaccine market, despite a seasonal decline in sales, Pfizer seems to be gaining market share, which could be seen as a positive sign. However, Bansal remains cautious due to the uncertainties in the COVID-19 portfolio and the potential impacts of the Part D redesign on Pfizer’s products starting from 2025. Hence, the Hold rating reflects the balance between these positive aspects and the underlying challenges that may affect Pfizer’s performance.

In another report released today, Barclays also maintained a Hold rating on the stock with a $28.00 price target.

 

[anonymous]

Wells Fargo on latest earnings: "......points out that the quality of this beat is questionable. It seems to be largely attributed to the unexpected adjustment of Paxlovid sales, which masks the underlying performance of Pfizer’s non-COVID portfolio. Additionally, while Pfizer’s ex-COVID business observed a year-over-year growth, it mostly stemmed from newly included SGEN products. Excluding these products, the growth was modest, which raises concerns about the core business’s growth trajectory moving forward.
Furthermore, the report indicates that while Comirnaty sales were down, this did play a role in the favorable gross margin for the quarter. Prevnar sales were solid, but there are looming risks with potential competition from upcoming products such as V116. In the RSV vaccine market, despite a seasonal decline in sales, Pfizer seems to be gaining market share, which could be seen as a positive sign. However, Bansal remains cautious due to the uncertainties in the COVID-19 portfolio and the potential impacts of the Part D redesign on Pfizer’s products starting from 2025. Hence, the Hold rating reflects the balance between these positive aspects and the underlying challenges that may affect Pfizer’s performance.

In another report released today, Barclays also maintained a Hold rating on the stock with a $28.00 price target.

It should be unacceptable for the board to look at each other say “we’re good at $28”. The objective of any publicly held company is to grow shareholder value. Its purpose to exist is not the enrichment of leadership. Near decade lows and pissed away the covid windfall of revenue and goodwill.

DO SOMETHING

 

[anonymous]

All the 175 year anniversary nonsense. Rear view means nothing. What is the plan for the next 175 weeks? It’s laughable they keep talking about “joy”. Do they even read the results of the silly surveys
Here’s what would bring me joy: run the business, demonstrate some focus and grow the company value. Cutting their company value in half and then moving sideways for a year is torturous, not joyous.
Clowns

 

[anonymous]

Down nearly 2% yesterday. AB had a chance yesterday at the Goldman Sachs presentation to make an impression with investors and begin to show PFE has a path forward. Even with a soft interview closing on the ludicrous Super Bowl ad, AB was not able to gain traction. In fact, the opening statements are very passive, as if things “happened” and we “had to understand” the reasons. Moron.

 

[anonymous]

A few investment houses and analysts now have PFE as a buy. Mostly due to how far the stock has dropped and the dividend. A couple cite the pipeline and cost reductions. None cite stellar leadership and decision making.
The target price is low to mid thirties over the next couple of years. Regardless, PFE remains mired in mid twenties and no break out looks forthcoming.
In other words, PFE is comparable to a CD or bond. CD if you want a dependable rate of return. Bond if you want returns and a potential upside should rates drop. PFE is not a compelling pharma bet with current leadership in place.

 

[anonymous]

Read the current article on PFE on CNBC. Our leadership sounds like rank amateurs and thinking like level one leaders. We’re going to be stuck in the mid twenties until changes are made at the top. PFE has the pieces to break upwards from the current levels but investors don’t trust PFE decision makers enough to buy in. No coherent message, no coherent plan.

 

[anonymous]

Read the current article on PFE on CNBC. Our leadership sounds like rank amateurs and thinking like level one leaders. We’re going to be stuck in the mid twenties until changes are made at the top. PFE has the pieces to break upwards from the current levels but investors don’t trust PFE decision makers enough to buy in. No coherent message, no coherent plan.

https://www.cnbc.com/2024/06/28/pfizer-stock-employees-covid-recovery.html

Lost faith of investors and employees. Time for AB to move on...

 

[anonymous]

Read the current article on PFE on CNBC. Our leadership sounds like rank amateurs and thinking like level one leaders. We’re going to be stuck in the mid twenties until changes are made at the top. PFE has the pieces to break upwards from the current levels but investors don’t trust PFE decision makers enough to buy in. No coherent message, no coherent plan.

Well we are counting on the CEO who put us in this mess to get us out of this mess, so…

 

[anonymous]

Shareholder here. What the fork is happening at this company????? This stock is really such a sad story, hopefully, someone will answer. Can anyone make a suggestion??? I have too much in my Retirement Fund and will pay HORRIBLE taxes if I sell. What to do?

 

[anonymous]

Shareholder here. What the fork is happening at this company????? This stock is really such a sad story, hopefully, someone will answer. Can anyone make a suggestion??? I have too much in my Retirement Fund and will pay HORRIBLE taxes if I sell. What to do?

The stock value over the past 15 years should tell you exactly who we are. Those that put all the blame on AB are missing the point.